CD40-Activating Monoclonal Antibodies Boost Response to Immunotherapy – Cancer Network
|
CD40-Activating Monoclonal Antibodies Boost Response to Immunotherapy
Cancer Network While chimeric antigen receptor (CAR) T-cell therapy and checkpoint inhibitors have ushered in a new era in immunotherapy, they only work in a limited number of patients and many of those who initially respond experience a relapse. Vonderheide said a … |
